Nautilus Biotechnology (NAUT) Capital Expenditures Growth (1y) (2021 - 2026)
Nautilus Biotechnology (NAUT) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Nautilus Biotechnology | 212.77 Mn | 116.90 Mn | - | 132.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.88% |
| Dec 31, 2025 | -3.94% |
| Sep 30, 2025 | -41.04% |
| Jun 30, 2025 | -22.66% |
| Mar 31, 2025 | -66.15% |
| Dec 31, 2024 | -38.50% |
| Sep 30, 2024 | -18.88% |
| Jun 30, 2024 | 10.58% |
| Mar 31, 2024 | -6.50% |
| Dec 31, 2023 | 80.35% |
| Sep 30, 2023 | -9.24% |
| Jun 30, 2023 | -28.88% |
| Mar 31, 2023 | 43.87% |
| Dec 31, 2022 | -76.77% |
| Sep 30, 2022 | 256.67% |
| Jun 30, 2022 | 22.60% |
| Mar 31, 2022 | -0.21% |
| Dec 31, 2021 | 224.34% |
| Sep 30, 2021 | 3.05% |